Inquis Medical Completes Enrollment in U.S. Pivotal IDE Trial of the Aventus Thrombectomy System Designed to Treat Patients with Pulmonary EmbolismMENLO PARK, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational Device Exemption (IDE) trial evaluating the safety and efficacy of the company’s Aventus Thrombectomy System for the treatment of pulmonary embolism (PE).
Inquis Medical Announces $40 Million Series B Financing to Accelerate Advancement of Aventus Thrombectomy System Addressing Venus Thromboembolic Diseases
Inquis Medical, a pioneering medical technology company specializing in advanced thrombectomy systems, today announced the successful closure of its $40 million Series B financing round. This oversubscribed round was led by Marshall Wace, a globally recognized investment firm, with strong participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. The funding positions Inquis Medical for significant growth and development as it advances its cutting-edge technologies and prepares for commercialization.
Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis MedicalRenowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology
